GSK Pays Up to $750M for Chimagen Trispecific T-Cell Engager in Multiple Myeloma
核心洞察
GSK has secured full global rights to Chimagen Biosciences (搜索)' unnamed trispecific T-cell engager (搜索) for multiple myeloma (搜索) in a deal worth up to $750 million.
The preclinical asset is designed to bind T cells while targeting two tumor-associated antigens, aiming for deeper responses and better tolerability than existing engagers.
GSK plans to begin Phase 1 testing in 2027, adding to a myeloma portfolio anchored by the BCMA (搜索)-directed antibody-drug conjugate Blenrep.
GSK has agreed to acquire full global rights to an investigational trispecific T-cell engager (搜索) (TCE) from privately held Chinese biotech Chimagen Biosciences (搜索), in a transaction with a total potential value of up to $750 million. The deal, announced Tuesday, covers a program that has not yet entered human trials and remains unnamed, with GSK disclosing neither the molecule's targets nor its architecture.
Under the terms, GSK will pay an undisclosed upfront fee, with Chimagen eligible to receive development and commercial milestone payments. The agreement remains subject to customary closing conditions. GSK plans to develop the candidate for multiple myeloma (搜索) and expects to initiate Phase 1 clinical trials in 2027.
A Trispecific Design Aimed at Tolerability
Existing T-cell engagers have demonstrated high efficacy in multiple myeloma (搜索) but carry significant tolerability issues that limit the breadth of clinical application and the timing of treatment. All four FDA-approved TCEs for multiple myeloma — Johnson & Johnson's Tecvayli (teclistamab) and Talvey (talquetamab), Pfizer's Elrexfio, and Regeneron's Lynozyfic — carry black box warnings citing the risks of excessive immune response and neurotoxicity.
Chimagen's trispecific candidate is designed to bind to a T cell while simultaneously targeting two tumor-associated antigens, rather than relying on a single tumor target. According to GSK, binding to both cancer targets could achieve a deeper and more durable response compared with currently available TCEs, while the engineered design — which brings T cells and tumor cells into proximity while blocking immune checkpoints — could improve tolerability and reduce off-target effects. Those properties, GSK says, could support use of the drug in a broader range of multiple myeloma (搜索) patients and as an earlier line of therapy.
"Today's deal secures a promising T cell engager and advances GSK's leadership goals in blood cancer," said Hesham Abdullah, GSK's senior vice president and global head of oncology R&D, in a prepared statement. "The agreement complements our existing portfolio in multiple myeloma (搜索), adding a new potential option to address the different needs of patients facing this complex disease."
Chimagen CEO Zhenhao Zhou said the collaboration combines the company's precision T-cell engager engineering technology with GSK's global development and commercialization capabilities, with the goal of redefining the treatment paradigm for multiple myeloma (搜索) patients.
The scientific claims rest on preclinical work that GSK has not described publicly, and the company has not disclosed the program code or trial details for the myeloma asset.
An Incurable Disease With an Urgent Need
Multiple myeloma (搜索) is the third most common blood cancer globally, behind lymphoma and leukemia, with approximately 180,000 people diagnosed each year. The disease remains treatable but incurable, and patients often hit a therapeutic wall once existing drugs fail, making novel-mechanism therapies particularly urgent. Market projections cited by GSK indicate the U.S. multiple myeloma T-cell engager market could surpass $10 billion by 2032.
GSK's commercial presence in the indication is anchored by Blenrep (belantamab mafodotin), a BCMA (搜索)-directed antibody-drug conjugate. In 2025, Blenrep combinations were approved for relapsed or refractory multiple myeloma (搜索) in the United States, the European Union, the United Kingdom, Japan and other markets, following the drug's earlier withdrawal. Additional trials are evaluating Blenrep as an earlier line of treatment. A trispecific TCE would attack the same disease by a different route — recruiting T cells rather than delivering a cytotoxic payload.
A Crowded Trispecific Race
GSK is entering an advanced competitive field. Johnson & Johnson's ramantamig (搜索) (JNJ-79635322) binds BCMA (搜索) and GPRC5D (搜索) on myeloma cells and CD3 (搜索) on T cells and has advanced into Phase 3, including a head-to-head trial against the BCMA/CD3 bispecific teclistamab after one to three prior lines that began in May. AbbVie is in Phase 1 testing with ABBV-2001 (搜索) (formerly ISB 2001), a TCE acquired from IGI Therapeutics that targets BCMA, CD38 (搜索) and CD3. Earlier this month, Roche agreed to pay $75 million upfront for global rights to SIM0660 (搜索), a trispecific TCE from Simcere Zaiming targeting CD79a, CD19 (搜索) and CD3 with potential applications across B cell-mediated diseases.
According to GlobalData's Pharmaceutical Intelligence Center, more than 100 ongoing Phase 3 studies are exploring treatment options for multiple myeloma (搜索), of which over six in ten are classed as immuno-oncology assets — the wider umbrella under which TCEs sit.
Second Chimagen Deal Deepens the Partnership
The agreement expands an existing relationship. On Oct. 29, 2024, GSK agreed to pay $300 million upfront for CMG1A46, a CD19 (搜索)/CD20 (搜索)-targeted T-cell engager, with up to $550 million more tied to development and commercial milestones. GSK presented that deal as an immunology move aimed at deep B-cell depletion in lupus and related autoimmune diseases, although Chimagen had already placed the drug in Phase 1 trials in leukemia and lymphoma. GSK's pipeline lists the molecule as a CD19/CD20/CD3 (搜索) trispecific antibody, and its Phase 1 study in B-cell-driven autoimmune rheumatic diseases, ELEVATE-1, began on Feb. 10 and is recruiting. CMG1A46 is currently being evaluated in Phase 1 studies for both B-cell malignancies and B-cell-dependent autoimmune diseases.
Oncology Rebuild Continues
The Chimagen deal is the latest step in GSK's return to oncology, a therapeutic area the company shed as part of a $20 billion three-part asset swap with Novartis in 2015. Under new CEO Luke Miels, oncology has been targeted as a core pillar of GSK's refreshed strategy, with the company aiming to expand its focus on blood and women's cancers into lung, gastrointestinal and other solid tumors through modalities including antibody-drug conjugates, TCEs and tyrosine kinase inhibitors.
GSK has assembled those assets largely from outside its own labs. On July 15 it completed its $10.6 billion acquisition of Nuvalent, adding three precision medicines for genetically defined lung cancers — its largest acquisition in more than a decade. On Sept. 3 it licensed rights outside Greater China to HUTCHMED's preclinical KRAS-EGFR conjugate HMPL-A830 (搜索) for $110 million upfront and as much as $1.295 billion in total. Earlier, in 2022, GSK acquired Sierra Oncology, a company focused on targeted therapies for rare cancers. GSK's oncology pipeline also includes antibody-drug conjugates targeting B7-H3 (搜索) and B7-H4 (搜索), as well as velzatinib (搜索), a selective KIT (搜索) tyrosine kinase inhibitor.
Analysts responded positively to the transaction. Berenberg (搜索) upgraded GSK's stock rating from "Hold" to "Buy," with analyst Kerry Holford writing in a note to clients that she supports the capital allocation and "much-needed pipeline replenishment." Berenberg noted that 10 of GSK's 11 new Phase 3 assets came from external licensing or acquisitions, with six of them each holding sales potential of at least £2 billion (approximately $2.7 billion). GSK shares rose as much as 1% in early London trading following the announcement, adding to gains made Monday when the company posted positive results from two other drugs in development for different types of lung cancer.
The deal reflects broader competition for oncology assets as large pharmaceutical companies face patent expirations on core products. In May, Merck & Co. (搜索) acquired Terns Pharmaceuticals for $6.7 billion, securing an oral candidate for Philadelphia chromosome-positive chronic myeloid leukemia. In April, Eli Lilly agreed to acquire Kelonia Therapeutics (搜索) for up to $7 billion to strengthen its cancer portfolio.